drugset / Trial / NCT05651828
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Phase 0
Recruiting
34 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare how well tolerated and effective four different dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed intermittent and continuous dosing regimen) work in people with advanced basal cell carcinoma.
Timeline
- Start
- 2023-03-23
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vismodegib | Small molecule | 150 mg | Oral |